key: cord-0684508-f06z8myb
authors: Ishack, Stephanie; Lipner, Shari R.
title: Bioinformatics and immunoinformatics to support COVID‐19 vaccine development
date: 2021-04-23
journal: J Med Virol
DOI: 10.1002/jmv.27017
sha: 2d50424073e62604e02a07a5cdd25370f3fb87f7
doc_id: 684508
cord_uid: f06z8myb

Severe acute respiratory syndrome coronavirus 2 has infected over 109 000 000 people with 2 423 443 deaths as of February 17, 2021. Currently, there are no approved or consistently effective treatments, and conventional vaccines may take several years for development and testing. In silico methods of bioinformatics, vaccinogenomics, immunoinformatics, structural biology, and molecular simulations can be used for more rapid and precise vaccine design. This paper highlights two major immunoinformatics strategies that are used in designing novel and effective vaccines and therapeutics: reverse vaccinology and structural vaccinology.

The novel coronavirus 2019 (COVID-19) infection, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 109 000 000 people with 2 423 443 deaths as of February 17, 2021. The mainstay of COVID-19 treatment is supportive care, but there is a high mortality rate, especially in older individuals and those with co-morbidities. Therefore, there is an urgent need to develop safe and effective vaccines. Conventional vaccinology (CV) methods are inadequate for this pandemic because of: (1) time-consuming antigen identification; (2) lack of antigenic diversity; (3) extensive pathogen cultivation in wet labs; and (4) high costs. [1] [2] In silico methods of bioinformatics, vaccinogenomics, immunoinformatics, structural biology, and molecular simulations can be effectively applied to advanced vaccine design, with faster processing time than CV. [1] [2] [3] In this paper, we highlight two major immunoinformatic strategies, reverse vaccinology (RV) and structural vaccinology (SV), and their application to potential COVID-19 vaccines.

phases. [1] [2] [3] Immunoinformatics is a branch of bioinformatics utilizing mathematical and computational approaches to process and develop immunological data and make predictions on immunity and disease pathogenesis. [2] [3] Epitope and multiepitope vaccines are composed of amino acid peptides that are immunogenic targets. Using the already sequenced COVID-19 genome, computational tools, and searchable databases can aid in predicting potential B and T cell epitopes for vaccine design, immunity protein analysis, and immunization modeling. 4 

RV and SV are subject to several limitations. There is evidence that antigen residues may become epitopes under specific conditions thereby complicating prediction methods. 3 Thus, RV requires advanced prediction algorithms to filter and analyze nonepitopic antigen surface residues. On rare occasions, sequence data from the high-throughput analysis may contain computing errors thereby affecting the quality of immunoinformatics predictions. The main disadvantage of SV is that newly predicted epitopes may be buried deep within the protein, making it difficult to detect by potential COVID-19 antibodies, and therefore, making the vaccine less effective. 2 

The rapid development of an effective and safe vaccine is necessary to reduce global mortality from COVID-19. RV and SV are promising techniques that can aid in the development of multiepitope vaccines against COVID-19 by inducing comprehensive B-and T-cell immunity. Since these immunoinformatics tools are readily available, continued leverage of these technologies will result in a shortened time to vaccine development.

An overview of bioinformatics tools for epitope prediction: implications on vaccine development

The impact of bioinformatics on vaccine design and development

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2

Design of multi epitope-based peptide vaccine against E protein of human COVID-19: an immunoinformatics approach

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning

The authors declare that there are no conflict of interests.

Stephanie Ishack https://orcid.org/0000-0002-2627-7791Shari R. Lipner https://orcid.org/0000-0001-5913-9304